Effectdossier · gearchiveerd kwartaal
VRTX
Vertex Pharmaceuticals Incorporated · Healthcare · Biotechnology
19Gevolgde houders
—Δ houders
46.47MGehouden aandelen
$21.77BGerapporteerde waarde
+0Nieuwe posities
−0Uitstappen
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 175 | -1 | 212.02M | $105.17B | +5 | −5 |
| Q1 2026 | 178 | 0 | 208.95M | $93.29B | +5 | −6 |
| Q4 2025 | 177 | -1 | 219.78M | $99.62B | +2 | −2 |
| Q3 2025 | 26 | +1 | 120.93M | $47.35B | +1 | −1 |
| Q2 2025 | 23 | +1 | 112.15M | $49.92B | +3 | −2 |
| Q1 2025 | 19 | -2 | 60.41M | $29.28B | — | −2 |
| Q4 2024 | 21 | +1 | 60.08M | $24.19B | +1 | — |
| Q3 2024 | 19 | 0 | 46.24M | $21.49B | — | — |
| Q2 2024 | 19 | — | 46.47M | $21.77B | — | — |
Wie het bezit · Q2 2024
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 26.71M | — | $12.52B | 2.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 6.33M | — | $2.96B | 0.3% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passief) | 6.33M | — | $2.96B | 0.3% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 4.09M | — | $1.92B | 0.3% | n/c | 1 | SEC ↗ |
| 12 | Norges Bank ✦ (passief) | 3.43M | — | $1.61B | 0.2% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 2.21M | — | $1.04B | 0.1% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 2.21M | — | $1.04B | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 1.57M | — | $734.20M | 1.2% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 536.11K | — | $251.29M | 0.4% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 536.11K | — | $251.29M | 0.4% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 536.11K | — | $251.29M | 0.4% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 536.11K | — | $251.29M | 0.4% | n/c | 1 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 335.16K | — | $157.10M | 0.3% | n/c | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 331.99K | — | $155.61M | 0.4% | n/c | 1 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 170.06K | — | $79.71M | 0.1% | n/c | 1 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 170.06K | — | $79.71M | 0.1% | n/c | 1 | SEC ↗ |
| 24 | Baillie Gifford ✦ | 167.62K | — | $78.56M | 0.1% | n/c | 1 | SEC ↗ |
| 25 | Baillie Gifford ✦ | 167.62K | — | $78.56M | 0.1% | n/c | 1 | SEC ↗ |
| 26 | Baillie Gifford ✦ | 167.62K | — | $78.56M | 0.1% | n/c | 1 | SEC ↗ |
| 27 | Baillie Gifford ✦ | 167.62K | — | $78.56M | 0.1% | n/c | 1 | SEC ↗ |
| 28 | Millennium Management ✦ | 142.76K | — | $66.91M | 0.1% | n/c | 1 | SEC ↗ |
| 29 | Marshall Wace ✦ | 127.00K | — | $59.53M | 0.1% | n/c | 1 | SEC ↗ |
| 30 | Citadel Advisors ✦ | 104.59K | — | $49.03M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Citadel Advisors ✦ | 104.59K | — | $49.03M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | ARK Investment Management ✦ | 75.46K | — | $35.37M | 0.3% | n/c | 1 | SEC ↗ |
| 33 | Tweedy, Browne ✦ | 54.35K | — | $25.47M | 1.2% | n/c | 1 | SEC ↗ |
| 34 | Bridgewater Associates ✦ | 33.23K | — | $15.58M | 0.1% | n/c | 1 | SEC ↗ |
| 35 | Fisher Asset Management ✦ | 28.11K | — | $13.17M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | Gotham Asset Management ✦ | 24.71K | — | $11.58M | 0.1% | n/c | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1,678 houders, 225.07M aandelen, $98.10B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q2 2024 ·
Methodologie ·
Verkrijg dit via de API